Expanding access to bispecific antibodies: lessons from the BiCARE shared-care model – IMS 2025 Nursing Symposium
Published:
When bispecific antibodies (BsAbs) first became available for relapsed or refractory myeloma, it was clear they had the potential to transform outcomes. Yet in my region of the United States, the Mountain West, we faced a serious challenge. Many patients live in rural areas, often hundreds of miles away from a major centre. For them, geographic isolation, limited infrastructure and a lack of local experience created major barriers to accessing these treatments.
Sign up and become a member of the Myeloma UK HCP Hub
Access exclusive content like this and join in the conversation.
Already have an account?